KR20160120735A - Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 - Google Patents

Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 Download PDF

Info

Publication number
KR20160120735A
KR20160120735A KR1020167023138A KR20167023138A KR20160120735A KR 20160120735 A KR20160120735 A KR 20160120735A KR 1020167023138 A KR1020167023138 A KR 1020167023138A KR 20167023138 A KR20167023138 A KR 20167023138A KR 20160120735 A KR20160120735 A KR 20160120735A
Authority
KR
South Korea
Prior art keywords
skin
subject
antagonist
pharmaceutical composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167023138A
Other languages
English (en)
Korean (ko)
Inventor
닐 그레이엄
마리우스 아르델레아누
앨런 라딘
제니퍼 디. 해밀턴
아리엘 테퍼
Original Assignee
리제너론 파아마슈티컬스, 인크.
사노피 바이오테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51663113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20160120735(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파아마슈티컬스, 인크., 사노피 바이오테크놀로지 filed Critical 리제너론 파아마슈티컬스, 인크.
Priority to KR1020227016206A priority Critical patent/KR102695088B1/ko
Publication of KR20160120735A publication Critical patent/KR20160120735A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020167023138A 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 Ceased KR20160120735A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227016206A KR102695088B1 (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461946237P 2014-02-28 2014-02-28
US61/946,237 2014-02-28
US201461952245P 2014-03-13 2014-03-13
US61/952,245 2014-03-13
US201461986371P 2014-04-30 2014-04-30
US61/986,371 2014-04-30
EP14306476.4 2014-09-24
EP14306476 2014-09-24
US201562100128P 2015-01-06 2015-01-06
US62/100,128 2015-01-06
PCT/US2015/017834 WO2015130975A1 (en) 2014-02-28 2015-02-26 Methods for treating skin infection by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227016206A Division KR102695088B1 (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법

Publications (1)

Publication Number Publication Date
KR20160120735A true KR20160120735A (ko) 2016-10-18

Family

ID=51663113

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167023138A Ceased KR20160120735A (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
KR1020227016206A Active KR102695088B1 (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
KR1020247026710A Pending KR20240128110A (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227016206A Active KR102695088B1 (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
KR1020247026710A Pending KR20240128110A (ko) 2014-02-28 2015-02-26 Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법

Country Status (13)

Country Link
US (3) US10370449B2 (cg-RX-API-DMAC7.html)
EP (2) EP3110848B1 (cg-RX-API-DMAC7.html)
JP (1) JP6526037B2 (cg-RX-API-DMAC7.html)
KR (3) KR20160120735A (cg-RX-API-DMAC7.html)
CN (1) CN106062000B (cg-RX-API-DMAC7.html)
AU (2) AU2015222951B2 (cg-RX-API-DMAC7.html)
CA (1) CA2939506C (cg-RX-API-DMAC7.html)
ES (1) ES2973858T3 (cg-RX-API-DMAC7.html)
MX (1) MX376691B (cg-RX-API-DMAC7.html)
PL (1) PL3110848T3 (cg-RX-API-DMAC7.html)
PT (1) PT3110848T (cg-RX-API-DMAC7.html)
RU (1) RU2704999C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015130975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN104755495A (zh) 2012-08-21 2015-07-01 赛诺菲 通过施用il-4r拮抗剂治疗或预防哮喘的方法
RU2698907C2 (ru) 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
MX376691B (es) 2014-02-28 2025-03-07 Regeneron Pharma Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
PT3506931T (pt) 2016-09-01 2024-08-21 Regeneron Pharma Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
US12208124B2 (en) * 2017-09-05 2025-01-28 Azitra Inc. Methods and compositions for treating inflammatory skin disease with recombinant microorganisms
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111514292B (zh) 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
WO2020180727A1 (en) * 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
US12398212B2 (en) 2019-07-16 2025-08-26 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
EP3992974A1 (en) * 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
JP2023504204A (ja) * 2019-12-09 2023-02-01 サノフィ・バイオテクノロジー デジタル的に識別されたｉｌ－４／ｉｌ－１３関連障害を治療する方法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
AU665763B2 (en) 1991-05-03 1996-01-18 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
EP2292665B1 (en) * 2000-05-26 2015-07-08 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
US20020002132A1 (en) * 2000-05-26 2002-01-03 Pluenneke John D. Use of interleukin-4 antagonists and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR100572408B1 (ko) 2000-07-26 2006-04-19 가부시키가이샤 호오도 진양성 조성물 및 창상치유촉진 조성물
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
JP2004529180A (ja) 2001-05-11 2004-09-24 ノバルティス アクチエンゲゼルシャフト ＩｇＥ関連障害を処置するのに使用するための組成物
EP1450855B1 (en) 2001-05-23 2009-08-26 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
ATE517855T1 (de) 2001-11-30 2011-08-15 Biogen Idec Inc Antikörper gegen chemotaktische monozytenproteine
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
CA2514840C (en) 2003-02-01 2017-11-07 Tanox, Inc. High affinity, anti-human ige antibodies
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
TWI356064B (en) 2003-11-07 2012-01-11 Immunex Corp Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008116149A2 (en) 2007-03-22 2008-09-25 Genentech, Inc. Apoptotic anti- ige antibodies binding the membrane-bound ige
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
WO2009061819A1 (en) 2007-11-05 2009-05-14 The Regents Of The University Of Colorado Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US20120004205A1 (en) 2008-12-01 2012-01-05 Cincinnati Children's Hospital Medical Center Il-13 induced gene signature for eosinophilic esophagitis
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN102596237A (zh) 2009-09-07 2012-07-18 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP2585075B8 (en) 2010-06-24 2021-09-22 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
NZ609557A (en) * 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
US20130324435A1 (en) 2011-01-06 2013-12-05 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9928344B2 (en) 2011-06-21 2018-03-27 Children's Hospital Medical Center Diagnostic methods of eosinophilic esophagitis
EP2763683A1 (en) 2011-10-06 2014-08-13 N.V. Nutricia Treatment of eosinophilic esophagitis
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
TW201334789A (zh) 2012-01-31 2013-09-01 Genentech Inc 抗ｉｇｅ抗體及其使用方法
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
CN104755495A (zh) 2012-08-21 2015-07-01 赛诺菲 通过施用il-4r拮抗剂治疗或预防哮喘的方法
RU2698907C2 (ru) 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
WO2014059178A1 (en) 2012-10-10 2014-04-17 Rhode Island Hospital Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
EP3620468A1 (en) 2013-02-05 2020-03-11 EngMab Sàrl Method for the selection of antibodies against bcma
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
PL3010539T3 (pl) 2013-06-21 2020-01-31 Sanofi Biotechnology Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
MX376691B (es) 2014-02-28 2025-03-07 Regeneron Pharma Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
CN109069625A (zh) 2016-02-19 2018-12-21 瑞泽恩制药公司 通过施用il-4r拮抗剂来增强疫苗功效的方法
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
PT3506931T (pt) 2016-09-01 2024-08-21 Regeneron Pharma Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r
RU2759630C2 (ru) 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
EP3582782B1 (en) 2017-02-17 2023-06-07 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
JP2023504204A (ja) 2019-12-09 2023-02-01 サノフィ・バイオテクノロジー デジタル的に識別されたｉｌ－４／ｉｌ－１３関連障害を治療する方法
IL298257A (en) 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
US20220220211A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist

Also Published As

Publication number Publication date
ES2973858T3 (es) 2024-06-24
CA2939506A1 (en) 2015-09-03
CA2939506C (en) 2022-08-23
CN106062000B (zh) 2021-05-28
EP4353254A2 (en) 2024-04-17
US20190367622A1 (en) 2019-12-05
PT3110848T (pt) 2024-03-05
MX376691B (es) 2025-03-07
JP2017512193A (ja) 2017-05-18
US11603408B2 (en) 2023-03-14
US20150246973A1 (en) 2015-09-03
US20230357416A1 (en) 2023-11-09
EP3110848B1 (en) 2024-02-14
AU2015222951B2 (en) 2020-06-11
EP4353254A3 (en) 2024-07-03
RU2016130056A3 (cg-RX-API-DMAC7.html) 2018-11-12
KR20220070544A (ko) 2022-05-31
EP3110848A1 (en) 2017-01-04
US10370449B2 (en) 2019-08-06
RU2704999C2 (ru) 2019-11-01
AU2020204350A1 (en) 2020-07-16
AU2020204350B2 (en) 2023-03-23
RU2016130056A (ru) 2018-04-02
MX2016011132A (es) 2016-12-08
WO2015130975A1 (en) 2015-09-03
PL3110848T3 (pl) 2024-06-10
KR20240128110A (ko) 2024-08-23
JP6526037B2 (ja) 2019-06-05
CN106062000A (zh) 2016-10-26
KR102695088B1 (ko) 2024-08-16
AU2015222951A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
US20230357416A1 (en) Methods for treating skin infection by administering an il-4r antagonist
US12502429B2 (en) Methods for treating atopic dermatitis by administering an IL-4R antagonist
US20190183973A1 (en) Methods for preventing or treating allergy by administering an il-4r antagonist
JP2021147383A (ja) アトピー性皮膚炎及び関連障害を処置するための方法
JP2024522620A (ja) アトピー性皮膚炎及び関連する障害の治療方法
HK40102414A (en) Methods for treating skin infection by administering an il-4r antagonist
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
HK1228934A1 (en) Methods for treating skin infection by administering an il-4r antagonist
HK1228934B (en) Methods for treating skin infection by administering an il-4r antagonist
HK40106043A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
HK40059877A (en) An il-4r antagonist antibody for use in treating atopic dermatitis by administering
HK40059877B (en) An il-4r antagonist antibody for use in treating atopic dermatitis by administering
HK1209132B (en) Methods for treating atopic dermatitis by administering an il-4r antagonist

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160824

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200212

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210713

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220119

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210713

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220119

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200212

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220414

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220321

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220119

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210713

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200212

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220513

PJ0201 Trial against decision of rejection

Patent event date: 20220513

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220414

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20220119

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2022101001132

Request date: 20220513

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101001132; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20220513

Effective date: 20230322

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20230322

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20220513

Decision date: 20230322

Appeal identifier: 2022101001132